X

Drug Profile

BMS 986189

Alternative Names: BMS-986189; BMS-986189-07

Latest Information Update: 07 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bristol-Myers Squibb; PeptiDream
Class
Mechanism of Action Programmed cell death 1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer
Discontinued Sepsis

Most Recent Events

07 Dec 2022 Discontinued - Phase-I for Sepsis (In volunteers) in USA (unspecified route)
06 Dec 2022 Preclinical trials in Japan in Germany (unspecified route) before December 2022 (PeptiDream pipeline, December 2022)
28 May 2020 No recent reports of development identified for preclinical development in Sepsis in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com